All relevant data are within the manuscript and its Supporting Information files. Protocols are available from <https://dx.doi.org/10.17504/protocols.io.bhnjj5cn>.

Introduction {#sec001}
============

Ankylosing spondylitis (AS) is a serum-negative connective tissue disease characterized by back pain and rigidity. Its etiology involves genetic, environmental, infectious, and immune factors. A number of studies have proved that genetic factors play a significant role in the pathogenesis of the disease. At least 36 susceptibility genes of AS have been found so far \[[@pone.0237219.ref001]\], among which human leukocyte antigen B27 (HLA-B27) has the closest association with the disease \[[@pone.0237219.ref002], [@pone.0237219.ref003]\], especially HLA-B\*2705, although HLA-B\*2706 and HLA-B\*2709 are not related to AS \[[@pone.0237219.ref004]--[@pone.0237219.ref006]\]. However, these genes can explain only 24.4% of the genetic predisposition toward AS, with HLA-B\*27 accounting for 20.1% and the remaining genes for 4.3%. This indicates that more than 75% of AS genetic susceptibility has yet to be found \[[@pone.0237219.ref001], [@pone.0237219.ref002], [@pone.0237219.ref007]\].

Some studies suggested that about 50%--60% of patients with AS also suffered from intestinal inflammation \[[@pone.0237219.ref002], [@pone.0237219.ref008]\], and 5%--10% of patients with AS had clinical evidence of inflammatory bowel disease (IBD), including Crohn\'s disease (CD) and ulcerative colitis (UC) \[[@pone.0237219.ref009], [@pone.0237219.ref010]\]. Another study found that the first-degree relatives of patients with AS were three times more likely to suffer from IBD compared with the general population \[[@pone.0237219.ref001], [@pone.0237219.ref011]\]. A genome-wide association study revealed that 20 of 31 AS-susceptibility genes overlapped with those of IBD; the same single-nucleotide polymorphisms (SNPs) had the same or similar effects in both diseases \[[@pone.0237219.ref001], [@pone.0237219.ref007], [@pone.0237219.ref012], [@pone.0237219.ref013]\]. In addition, the genes linked to AS involved various aspects of infection and immunology \[[@pone.0237219.ref014]\]. Therefore, it is promising to further search for susceptibility genes of AS among infection-related genes, especially relevant genes of IBD.

The human fucosyltransferase2 (*FUT2*) gene encodes α1,2-L-fucosyltransferase, which catalyzes the biosynthesis of type-1 H (Le^d^), a blood group antigen, using a type-1 precursor (Le^c^) and fucose. Type-1 H is also a precursor of several other blood group antigens, such as type-1 A or type-1 B. An individual having functional *FUT2* (*Se*) is called a secretor, whose fluids and secretions may contain soluble A, B, and H antigens. Otherwise, an individual with two null *FUT2* alleles (*se*) is called a non-secretor, who cannot synthesize these antigens. The human *FUT3* gene encodes α1,3/4-L-fucosyltransferase, which catalyzes the synthesis of Le^a^ antigen in non-secretors using Le^c^ and fucose, or catalyzes the synthesis of Le^b^ in secretors using type-1 H and fucose. Therefore, non-secretors with functional *FUT3* (*Le*) exhibit the Le(a+b-) serotype, secretors with *Le* exhibit the Le(a-b+) serotype, and individuals with two null *FUT3* alleles (*le*) present the Le(a-b-) serotype despite their secretor status \[[@pone.0237219.ref015]\]. The type-1 A, B, H, and Lewis antigens (such as Le^b^) are widely distributed in human fluids and secretions and on the surface of genitourinary and gastrointestinal epithelial cells. Hence, they are called histo-blood group antigens (HBGAs).

*FUT2* and *FUT3* genes are closely related to gut inflammation. The expression of both *FUT2* and *FUT3* genes needs the participation of host intestinal flora \[[@pone.0237219.ref016]--[@pone.0237219.ref019]\]. Meanwhile, non-secretors are more susceptible to CD \[[@pone.0237219.ref016], [@pone.0237219.ref020]\]; *FUT3* gene polymorphisms and expression in the intestinal tract are associated with the susceptibility to UC \[[@pone.0237219.ref021]\]. Therefore, it is supposed that *FUT2*, *FUT3*, and HBGAs may play certain roles in the pathogenesis of AS and relevant intestinal inflammation. The aim of this study was to explore the associations between *FUT2/FUT3* polymorphisms and AS in an east Chinese population.

Materials and methods {#sec002}
=====================

Participants {#sec003}
------------

A total of 673 patients with AS were selected at the Clinic of Rheumatology and Immunology, the First Affiliated Hospital of Anhui Medical University from January 2015 to June 2018. All the patients were diagnosed by senior rheumatologists according to the New York Diagnostic Criteria (revised in 1984). Meanwhile, 687 age- and sex-matched healthy controls were recruited from the Health Checkup Center of the hospital. All the participants came from east China, mostly from Anhui Province. They had no underlying diseases such as liver, kidney, and cardiovascular or cerebrovascular diseases. In addition, they had not suffered from infectious diseases, such as acute intestinal inflammation, within six months before sampling; had not undergone surgery within one year; and had not taken non-steroidal anti-inflammatory drugs, glucocorticoids, traditional Chinese medicine, and other anti-rheumatic drugs within three months prior to sampling. Furthermore, none of the healthy controls had family history of rheumatic and autoimmune diseases. All the participants were informed of the study in detail and voluntarily signed a written informed consent prior to their participation. Each of the patients with AS then filled in a questionnaire on personal diet, living habits, and health status. The controls provided their health information orally. Subsequently, the samples of peripheral blood were collected from all the participants with anticoagulant tubes containing ethylene diamine tetraacetic acid (EDTA).

This case--control study fully complied with the Declaration of Helsinki and local laws, and was approved by the Biomedical Ethics Committee of Anhui Medical University (demonstration report number: 20150117). After signing the written informed consent, researchers were forbidden from accessing any identity information of the participants.

DNA preparation and genotyping {#sec004}
------------------------------

The extraction of genomic DNA from the specimens of blood was carried out with a QIAamp DNA Blood Mini Kit (Qiagen, Germany) according to the manufacturer's protocols. The prepared DNA solutions were cryopreserved in a -80ºC refrigerator until testing. The selection of SNPs for genotyping was accomplished based on their frequencies in the Oriental population and their roles in the determination of HBGAs ([Table 1](#pone.0237219.t001){ref-type="table"}). Genotyping was conducted using a patented method named SNPscan \[[@pone.0237219.ref022]\], which was based on double-ligation reactions and a multiplex fluorescence polymerase chain reaction (PCR), with a custom-made 48-Plex SNPscan Kit (Genesky, China). The PCR products were subsequently separated and detected with an ABI 3730 XL sequencer (ABI, Carlsbad, CA 92008, USA) using capillary electrophoresis. To meet the technical requirements of the SNPscan test, the complementary bases of rs28362459 and rs812936 were actually tested.

10.1371/journal.pone.0237219.t001

###### SNP information and primer sequences used for genotyping.

![](pone.0237219.t001){#pone.0237219.t001g}

  SNP                   Gene     Chromosome   Position   Primer                        
  --------------------- -------- ------------ ---------- ----------------------------- -----------------------------
  rs1047781 (385A\>T)   *FUT2*   19           48703374   AR-                           `CGGACGTACTCCCCCGGCAT`
                                              TR-        `CGGACGTACTCCCCCGGCAA`        
                                              3R-        `GTGGCGGTATTCCTCCTCCA`        
  rs1800028 (571C\>T)   *FUT2*   19           48703560   CR-                           `GCATGACATGGACATAGTCCCCACG`
                                              TR-        `GCATGACATGGACATAGTCCCCACA`   
                                              3R-        `GCGAACATGGACCCCTACAA`        
  rs1800030 (849G\>A)   *FUT2*   19           48703838   GF-                           `TTGGGACGTTCGGGATCAGG`
                                              AF-        `TTGGGACGTTCGGGATCAGA`        
                                              3F-        `GCCGCATACCTCACGGGCGG`        
  rs28362459 (59T\>G)   *FUT3*   19           5844781    AR-                           `CGCCGCTGTCTGGCCGCTCT`
                                              CR-        `CGCCGCTGTCTGGCCGCTCG`        
                                              3R-        `GCTATTTCAGCTGCTGGTGGC`       
  rs812936 (202T\>C)    *FUT3*   19           5844638    AF-                           `GGATGTGGAAAGGCCATGTGCA`
                                              GF-        `GGATGTGGAAAGGCCATGTACG`      
                                              3F-        `TAGCAGGATCAGGAGGGTGGG`       

SNP, single-nucleotide polymorphism; *FUT 2*, fucosyltransferase 2; *FUT 3*, fucosyltransferase 3.

DNA preparation and genotyping were completed at Department of Blood Transfusion, the First Affiliated Hospital of USTC. For quality control, 4% of randomly chosen DNA samples were genotyped repeatedly at Genesky Biotechnologies Inc., Shanghai, China.

According to the principle of blind test, all the samples were randomly coded with a test number before DNA extraction. No participant's information for any specimens was available until the data analysis.

Inference of phenotype {#sec005}
----------------------

According to the Blood Group Mutation Database (archived now) \[[@pone.0237219.ref023]\] and the blood typing data of local patients, a sample with any variant of rs1047781-TT, rs1800028-TT, or rs1800030-AA was classified as non-secretor (*se*), otherwise as secretor (*Se*). Similarly, an individual with rs28362459-GG or rs812936-CC was sorted as Lewis negative (*le*), otherwise as Lewis positive (*Le*). Lewis serotypes were inferred as follows: Lewis-negative individuals, both secretors and non-secretors, were classified as Le(a-b-). Lewis-positive secretors were sorted as Le(a-b+), and Lewis-positive non-secretors as Le(a+b-).

Data analyses {#sec006}
-------------

The questionnaire and the genotyping data of all the participants were collected, input into a database, and proofread twice. The frequencies of each genotype, allele, secretor status, Lewis status, serotype, and haplotype were compared between the cases and the controls. Potential interactions among these factors, age, and sex were also analyzed. The effects of *FUT2/FUT3* polymorphisms on the Bath ankylosing spondylitis disease activity index (BASDAI) and the Bath ankylosing spondylitis functional index (BASFI), which were usually used to measure the disease severity of AS, were assessed specially.

Statistical analyses {#sec007}
--------------------

Quantitative variables with normal distribution were reported as mean ± standard deviation (SD); otherwise, as median (interquartile range, IQR). The frequency differences in sex, genotype, allele, and phenotype between the cases and the controls were all analyzed using the chi-square test. The difference in age was analyzed using the independent samples *t* test. The associations between *FUT2/FUT3* and clinical indexes of AS were analyzed using the Mann--Whitney *U* test for two independent samples and the Kruskal--Wallis test for *K* independent samples. If there was no statistical difference in a variable between the treated and untreated patients, the two parts of data would be combined. The cases with missing values were excluded test-by-test according to the results of the Missing Value Analysis. Two-factor interactions on a multiplicative scale were assessed employing the binary logistic regression. All these analyses were completed using SPSS Statistics 23.0 (IBM, USA).

The analyses of two-factor interaction on an additive scale were carried out adopting the indexes proposed by Rothman and Hosmer \[[@pone.0237219.ref024], [@pone.0237219.ref025]\]. The estimations of relative excess risk due to interaction (RERI), attributable proportion due to interaction (AP), and synergy index (S) were accomplished using the Excel sheet written by Andersson et al \[[@pone.0237219.ref026]\]. If the confidence interval (CI) of RERI and AP did not contain 0, and the CI of S did not include 1, it was regarded as having additive interaction between the two factors.

Multifactor interaction analyses were performed using Multifactor Dimensionality Reduction (MDR) 3.0.2. Haplotype analyses and Hardy--Weinberg equilibrium tests were conducted using Haploview 4.2. *P* values of haplotype analyses were corrected for multiple testing bias using permutation test. Sample size estimation and power analyses were conducted using PASS 11.0.7. *P* values of other multiple comparisons were all corrected adopting the false discovery rate (FDR) method using R 3.6.2. *P* or corrected *P* (if applicable) \<0.05 was regarded as statistically significant.

Results {#sec008}
=======

Demographic and clinical characteristics of participants {#sec009}
--------------------------------------------------------

A total of 925 patients with AS were enlisted and 673 of them (546 males and 127 females) agreed to join this study eventually. Meanwhile, 687 (560 males and 127 females) of 892 eligible healthy controls consented to participate (control/case ≈ 1.021). The male/female ratio (4.30 vs 4.41, ***χ***^**2**^ **=** 0.856, *P* = 0.890) and the age \[26.0 (11.0) vs 27.0 (10.0) years, *Z* = -1.118, *P* = 0.264\] of the cases and controls were comparable ([S1 Table](#pone.0237219.s004){ref-type="supplementary-material"}). Furthermore, the genotype frequencies of all the five SNPs included in this study conformed to Hardy--Weinberg equilibrium (all *P* \> 0.05). Raw data of genotyping outcomes were partly provided in [S1 Fig](#pone.0237219.s002){ref-type="supplementary-material"}, and main lifestyles and clinical characteristics of the patients with AS were listed in [S1 Table](#pone.0237219.s004){ref-type="supplementary-material"}.

Associations between *FUT2*/*FUT3* polymorphisms and human susceptibility to AS {#sec010}
-------------------------------------------------------------------------------

The genotype frequencies of the five SNPs included in this study showed no differences between the cases and the controls, both in the total participants and in either sex subgroup (all *P*~corrected~ \> 0.05) ([Table 2](#pone.0237219.t002){ref-type="table"}). At the allele level, however, a significant frequency difference of rs28362459 was observed between the patients with AS and the healthy controls among the total participants \[*χ*^2^ = 7.515, *P*~corrected~ = 0.030; adjusted odds ratio (OR~adjusted~)~G/T~ = 0.782; 95% CI, 0.650--0.941; Power = 0.8\] ([Table 2](#pone.0237219.t002){ref-type="table"}, [S2 Fig](#pone.0237219.s003){ref-type="supplementary-material"}). Rs28362459-G, which usually leads to a Lewis-negative phenotype, showed a lower frequency in the patients with AS than in the healthy controls (20.3% vs 24.7%). No differences in allele frequency were found in the remaining SNPs among the total participants (all *P*~corrected~ \> 0.05). In the male and female subgroups, all the five SNPs showed no significant differences in allele frequency between the cases and the controls (all *P*~corrected~ \> 0.05). These suggested that the polymorphisms of rs28362459 were probably associated with human susceptibility to AS, and the allele rs28362459-G might be a protective factor for AS.

10.1371/journal.pone.0237219.t002

###### Comparisons of genotype/allele frequency between cases and controls in the total participants.
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  Genotype/Allele   Case \[n (%)\]   Control \[n (%)\]   *χ*^2^   *P*/*P*~corrected~ value[^a^](#t002fn001){ref-type="table-fn"}   OR~adjusted~ (95.0% CI)[^b^](#t002fn002){ref-type="table-fn"}                                                          
  ----------------- ---------------- ------------------- -------- ---------------------------------------------------------------- --------------------------------------------------------------- ------- ----------- ------------ ---------- ---------- --------
  rs1047781         AA               216                 (32.1)   219                                                              (31.9)                                                          2.467   0.291       /0.728                             
  AT                333              (49.5)              319      (46.4)                                                                                                                                               1.043        (0.816--   1.334)     
  TT                124              (18.4)              149      (21.7)                                                                                                                                               0.877        (0.644--   1.193)     
  A                 765              (56.8)              757      (55.1)                                                           0.836                                                           0.361   /0.903                                         
  T                 581              (43.2)              617      (44.9)                                                                                                                                               0.975        (0.835--   1.140)     
  rs1800028         CC               665                 (98.8)   680                                                              (99.0)                                                          0.090   0.764       /0.955                             
                    CT               8                   (1.2)    7                                                                (1.0)                                                                                            1.110      (0.398--   3.092)
                    C                1338                (99.4)   1367                                                             (99.5)                                                          0.089   0.765       /0.956                             
                    T                8                   (0.6)    7                                                                (0.5)                                                                                            1.204      (0.434--   3.335)
  rs1800030         GA               7                   (1.0)    7                                                                (1.0)                                                           0.001   0.969       /0.969                             
                    GG               666                 (99.0)   680                                                              (99.0)                                                                                           1.028      (0.354--   2.982)
                    G                1339                (99.5)   1367                                                             (99.5)                                                          0.001   0.969       /0.969                             
                    A                7                   (0.5)    7                                                                (0.5)                                                                                            1.073      (0.374--   3.079)
  rs28362459        TT               429                 (63.7)   393                                                              (57.2)                                                          7.384   0.025       /0.125                             
                    GT               215                 (31.9)   249                                                              (36.2)                                                                                           0.795      (0.632--   0.996)
                    GG               29                  (4.3)    45                                                               (6.6)                                                                                            0.608      (0.373--   0.990)
                    T                1073                (79.7)   1035                                                             (75.3)                                                          7.515   **0.006**   **/0.030**                         
                    G                273                 (20.3)   339                                                              (24.7)                                                                                           0.782      (0.650--   0.941)
  rs812936          TT               625                 (92.9)   642                                                              (93.4)                                                          1.128   0.569       /0.948                             
                    CT               47                  (7.0)    45                                                               (6.6)                                                                                            1.045      (0.683--   1.601)
                    CC               1                   (0.1)    0                                                                (0.0)                                                                                                       \-\--      
                    T                1297                (96.4)   1329                                                             (96.7)                                                          0.272   0.602       /0.956                             
                    C                49                  (3.6)    45                                                               (3.3)                                                                                            1.162      (0.768--   1.757)

^a^ *P*~corrected~ value (*P* value corrected using the FDR method). Boldface indicates statistical significance.

^b^ OR~adjusted~ (crude OR adjusted for age, sex, and the remaining SNPs). OR, odds ratio; CI, confidence interval.

Haplotype analyses of the total participants revealed significant differences between the cases and the controls in the frequencies of haplotype TT (rs812936--rs28362459) (*χ*^2^ = 5.663, *P*~permutation~ = 0.039; Power = 0.7; D\' = 0.931) and TG (rs812936--rs28362459) (*χ*^2^ = 7.456, *P*~permutation~ = 0.013; Power = 0.8; D\' = 0.931). A significant difference in the frequencies of haplotype TG (rs812936-rs28362459) was also found between the two groups in the female subgroup (χ^2^ = 5.624, *P*~permutation~ = 0.047; Power = 0.7; D\' = 0.916) ([Table 3](#pone.0237219.t003){ref-type="table"}). These results further suggested a link between *FUT3* polymorphisms and the susceptibility to AS.

10.1371/journal.pone.0237219.t003

###### Frequency differences in haplotypes between cases and controls.
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  Group    Block                             Haplotype   Frequency      Case ratio     Control ratio   *χ*^2^            *P*/*P*~permutation~ value[^a^](#t003fn001){ref-type="table-fn"}
  -------- --------------------------------- ----------- -------------- -------------- --------------- ----------------- ------------------------------------------------------------------
  Total    rs1047781--rs1800028--rs1800030   ACG         0.549          750.0:596.0    743.0:631.0     0.743             0.389/0.794
           TCG                               0.440       581.0:765.0    617.0:757.0    0.836           0.361/0.756       
           rs812936--rs28362459              TT          0.744          1028.5:317.5   995.2:378.8     5.663             **0.017/0.039**
           TG                                0.221       268.5:1077.5   333.8:1040.2   7.456           **0.006/0.013**   
           CT                                0.031       44.5:1301.5    39.8:1334.2    0.375           0.540/0.916       
  Male     rs1047781--rs1800028--rs1800030   ACG         0.549          608.0:484.0    606.0:514.0     0.551             0.458/0.853
           TCG                               0.441       474.0:618.0    501.0:619.0    0.394           0.530/0.909       
           rs812936--rs28362459              TT          0.741          828.1:263.9    812.0:308.0     3.198             0.074/0.227
           TG                                0.223       224.9:867.1    269.0:851.0    3.727           0.054/0.163       
           CT                                0.033       36.9:1055.1    37.0:1083.0    0.011           0.917/1.000       
  Female   rs1047781--rs1800028--rs1800030   ACG         0.553          144.0:110.0    137.0:117.0     0.390             0.532/0.931
           TCG                               0.435       105.0:149.0    116.0:138.0    0.969           0.325/0.715       
           rs812936--rs28362459              TT          0.752          200.1:53.9     182.1:71.9      3.424             0.064/0.170
           TG                                0.216       43.9:210.1     65.9:188.1     5.624           **0.018/0.047**   
           CT                                0.023       7.9:246.1      3.9:250.1      1.390           0.238/0.583       

^a^ *P*~permutation~ value (P value of permutation test). Boldface indicates statistical significance.

In the analyses of two-factor interaction, multiplicative interactions were found in the total participants between rs28362459-TG and age (OR~adjusted~ = 0.071; 95% CI, 0.005--0.980; *P*~corrected~ = 0.048), and rs28362459-TG and sex (OR~adjusted~ = 0.549; 95% CI, 0.305--0.989; *P*~corrected~ = 0.046). In the male subgroup, a multiplicative interaction was observed between rs28362459-TG and age (OR~adjusted~ = 0.032; 95% CI, 0.002--0.616; *P*~corrected~ = 0.022). In the female subgroup, no multiplicative interactions were found (all *P*~corrected~ \> 0.05). Moreover, additive interactions were observed between rs1047781 and rs28362459 in the total participants (RERI, 0.235--3.167; AP, 0.226--0.762; S, 1.109--9.792), the male subgroup (RERI, 0.669--3.282; AP, 0.327--0.727; S, 1.246--10.173), and the female subgroup (RERI, 0.334--1.499; AP, 0.181--0.565; S, 1.001--7.251) ([Fig 1A, 1C and 1E](#pone.0237219.g001){ref-type="fig"}). No multifactor interactions were found in the total participants and either subgroup (all *P* \> 0.05).

![Additive interactions between rs1047781 and rs28362459, and Lewis status and secretor status.\
(A, C, and E) Interactions on an additive scale between rs1047781and rs28362459 for total participants, male subgroup, and female subgroup, respectively. (B, D, and F) Interactions on an additive scale between Lewis status and secretor status for the total participants, the male subgroup, and the female subgroup, respectively.](pone.0237219.g001){#pone.0237219.g001}

Association between *FUT2*/*FUT3* phenotypes and human susceptibility to AS {#sec011}
---------------------------------------------------------------------------

At the phenotypic level, no frequency differences in the secretor status were found between the cases and the controls, whether in the total participants or either sex subgroup (all *P*~corrected~ \> 0.05). Similarly, no differences were observed between the patients and the controls in terms of the frequencies of the Lewis status (all *P*~corrected~ \> 0.05) and the Lewis serotype (all *P*~corrected~ \> 0.05) ([Table 4](#pone.0237219.t004){ref-type="table"}).

10.1371/journal.pone.0237219.t004

###### Frequency differences in *FUT2/FUT3* phenotypes between cases and controls.
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  Participant   Phenotype/Serotype   Case \[n (%)\]   Control \[n (%)\]   *χ*^2^   *P*/*P*~corrected~ value[^a^](#t004fn001){ref-type="table-fn"}   ORadjusted (95.0% CI)[^b^](#t004fn002){ref-type="table-fn"}                                       
  ------------- -------------------- ---------------- ------------------- -------- ---------------------------------------------------------------- ------------------------------------------------------------- ------- -------- ------- ---------- --------
  Total         *se*                 124              (18.4)              149      (21.7)                                                           2.257                                                         0.133   /0.160                      
                *Se*                 549              (81.6)              538      (78.3)                                                                                                                                          1.201   (0.919--   1.569)
                *le*                 30               (4.5)               45       (6.6)                                                            2.857                                                         0.091   /0.160                      
                *Le*                 643              (95.5)              642      (93.4)                                                                                                                                          1.474   (0.916--   2.372)
                Le(a-b+)             524              (77.9)              503      (73.2)                                                           4.836                                                         0.089   /0.160                      
                Le(a+b-)             119              (17.7)              139      (20.2)                                                                                                                                          0.841   (0.639--   1.107)
                Le(a-b-)             30               (4.5)               45       (6.6)                                                                                                                                           0.656   (0.406--   1.058)
  Male          *se*                 98               (17.9)              123      (22.0)                                                           2.788                                                         0.095   /0.180                      
                *Se*                 448              (82.1)              437      (78.0)                                                                                                                                          1.278   (0.948--   1.721)
                *le*                 27               (4.9)               39       (7.0)                                                            2.009                                                         0.156   /0.180                      
                *Le*                 519              (95.1)              521      (93.0)                                                                                                                                          1.427   (0.860--   2.368)
                Le(a-b+)             425              (77.8)              406      (72.5)                                                           4.550                                                         0.103   /0.180                      
                Le(a+b-)             94               (17.2)              115      (20.5)                                                                                                                                          0.983   (0.684--   1.412)
                Le(a-b-)             27               (4.9)               39       (7.0)                                                                                                                                           0.830   (0.448--   1.540)
  Female        *se*                 26               (20.5)              26       (20.5)                                                           0.000                                                         1.000   /1.000                      
                *Se*                 101              (79.5)              101      (79.5)                                                                                                                                          0.960   (0.517--   1.784)
                *le*                 3                (2.4)               6        (4.7)                                                            1.037                                                         0.309   /1.000                      
                *Le*                 124              (97.6)              121      (95.3)                                                                                                                                          1.657   (0.400--   6.869)
                Le(a-b+)             99               (78.0)              97       (76.4)                                                           1.041                                                         0.594   /1.000                      
                Le(a+b-)             25               (19.7)              24       (18.9)                                                                                                                                          1.043   (0.554--   1.966)
                Le(a-b-)             3                (2.4)               6        (4.7)                                                                                                                                           0.612   (0.147--   2.543)

^a^ *P*~corrected~ value (*P* value corrected using the FDR method).

^b^ OR~adjusted~ (crude OR adjusted for age, sex, and the remaining factors). OR, odds ratio; CI, confidence interval.

No multiplicative interactions were found at phenotypic level in all the factors (all *P*~corrected~ \> 0.05). Additive interactions were found between the Lewis status and the secretor status in the total participants (RERI, 0.747--2.338; AP, 0.247--0.590; S, 1.225--4.513), the male subgroup (RERI, 0.840--2.706; AP, 0.272--0.610; S, 1.285--4.567), and the female subgroup (RERI, 0.396--1.614; AP, 0.147--0.528; S, 1.031--4.009) ([Fig 1B, 1D and 1F](#pone.0237219.g001){ref-type="fig"}). No multifactor interactions were found at phenotypic level (all *P* \> 0.05). These findings suggested that the phenotypes of *FUT2* and *FUT3*, and their co-determined Lewis serotypes, might not correlate with the predisposition to AS.

Correlations between *FUT2*/*FUT3* polymorphisms and BASFI/BASDAI {#sec012}
-----------------------------------------------------------------

To explore the links between the gene polymorphisms and the clinical manifestations of AS, association analyses were conducted at the gene and phenotypic levels. No associations were found between the gene polymorphisms and the BASFI/BASDAI (all *P*~corrected~ \> 0.05). However, at the item level, the results revealed that rs1800030-A was related to an alleviated morning stiffness (the sixth item of the BASDAI, BASDAI 6; BASDAI 6~GA~: BASDAI 6~GG~ = 0.0: 1.0; *Z* = -2.575, *P*~corrected~ = 0.045; Power = 1.0), while rs28362459-G was related to a severer limitation with regard to standing without support (the sixth question of the BASFI, BASFI 6) among patients with AS (BASFI 6~GG~: BASFI 6~GT~: BASFI 6~TT~ = 1.0: 0.0: 0.0; *χ*^2^ = 10.089, *P*~corrected~ = 0.030; Power = 0.8). Lewis-positive (*Le*) patients suffered less functional loss compared with Lewis-negative (*le*) patients in terms of BASFI 6 (*Z* = -2.319, *P*~corrected~ = 0.040; Power = 0.3) and bending forward from the waist (BASFI 2; Z = -2.333, *P*~corrected~ = 0.040; Power = 0.6) ([Table 5](#pone.0237219.t005){ref-type="table"}). In line with this, both Le(a+b-) and Le(a-b+) groups had less functional limitations in BASFI 6 (*χ*^2^ = 7.220, *P*~corrected~ = 0.027; Power = 0.3) and BASFI 2 (*χ*^2^ = 6.419, *P*~corrected~ = 0.040; Power = 0.5) compared with the Le(a-b-) patients. In addition, the Le(a+b-) and Le(a-b+) patients also suffered less than the Le(a-b-) ones in regard to reaching up to a high shelf (BASFI 3; *χ*^2^ = 6.848, *P*~corrected~ = 0.033; Power = 0.5) and climbing 12--15 steps independently (BASFI 7; *χ*^2^ = 6.800, *P*~corrected~ = 0.033; Power = 0.3) ([Table 5](#pone.0237219.t005){ref-type="table"}). No significant differences were observed between the remaining factors and clinical variables (all *P*~corrected~ \> 0.05). These results indicated that the polymorphisms of *FUT2* and *FUT3* were likely to be associated with the symptoms of AS, and rs28362459-G might aggravate relevant symptoms.

10.1371/journal.pone.0237219.t005

###### Associations between *FUT2/FUT3* gene polymorphisms and the indexes of AS.

![](pone.0237219.t005){#pone.0237219.t005g}

  Factor       Variable(description)[^a^](#t005fn001){ref-type="table-fn"}                               Subgroup   *n*        Variable value \[median (IQR)\]   *Z* /*χ*^2^[^b^](#t005fn002){ref-type="table-fn"}   *P*/*P*~corrected~ value[^c^](#t005fn003){ref-type="table-fn"}   
  ------------ ----------------------------------------------------------------------------------------- ---------- ---------- --------------------------------- --------------------------------------------------- ---------------------------------------------------------------- ------------
  rs1800030    BASDAI 6 (Morning stiffness severity)                                                     GG         665        1.0 (4.0)                         --2.575                                             **0.009**                                                        **/0.045**
               GA                                                                                        7          0.0(0.0)                                                                                                                                                          
  rs28362459   BASFI 6 (Standing unsupported for 10 min without discomfort)                              TT         429        0.0(2.0)                          10.089                                              **0.006**                                                        **/0.030**
               GT                                                                                        215        0.0(3.0)                                                                                                                                                          
               GG                                                                                        29         1.0(4.0)                                                                                                                                                          
  Lewis        BASFI 2 (Bending forward from the waist to pick up a pen from the floor without an aid)   *le*       30         2.0(6.2)                          --2.333                                             **0.020**                                                        **/0.040**
               *Le*                                                                                      643        0.0(4.0)                                                                                                                                                          
               BASFI 6 (Standing unsupported for 10 min without discomfort)                              *le*       30         1.0(4.0)                          --2.319                                             **0.020**                                                        **/0.040**
               *Le*                                                                                      643        0.0(2.0)                                                                                                                                                          
  Serotype     BASFI 2 (Bending forward from the waist to pick up a pen from the floor without an aid)   Le(a-b+)   524        0.0(4.0)                          6.419                                               **0.040**                                                        **/0.040**
               Le(a+b-)                                                                                  119        0.0(4.0)                                                                                                                                                          
               Le(a-b-)                                                                                  30         2.0(6.2)                                                                                                                                                          
               BASFI 3 (Reaching up to a high shelf without help or aids)                                Le(a-b+)   514        0.0(2.0)                          6.848                                               **0.033**                                                        **/0.033**
               Le(a+b-)                                                                                  118        0.0(2.0)                                                                                                                                                          
               Le(a-b-)                                                                                  30         1.5(4.2)                                                                                                                                                          
               BASFI 6 (Standing unsupported for 10 min without discomfort)                              Le(a-b+)   524        0.0(2.0)                          7.220                                               **0.027**                                                        **/0.027**
               Le(a+b-)                                                                                  119        0.0(2.0)                                                                                                                                                          
               Le(a-b-)                                                                                  30         1.0(4.0)                                                                                                                                                          
               BASFI 7 (climbing 12--15 steps without using a handrail or walking aid)                   Le(a-b+)   524        0.0(2.0)                          6.800                                               **0.033**                                                        **/0.033**
               Le(a+b-)                                                                                  119        0.0(2.0)                                                                                                                                                          
               Le(a-b-)                                                                                  30         1.0(4.0)                                                                                                                                                          

^a^ The clinical manifestations of ankylosing spondylitis were presented as one of the items of Bath ankylosing spondylitis disease activity index (BASDAI) or Bath ankylosing spondylitis functional index (BASFI) and the corresponding description.

^b^ *Z* and *χ*^2^ were statistical outcomes of the Mann--Whitney *U* test and the Kruskal--Wallis test, respectively.

^c^ *P*~corrected~ value (*P* value corrected using the FDR method). Boldface indicates statistical significance. AS, ankylosing spondylitis; IQR, interquartile range.

Discussion {#sec013}
==========

In view of a large degree of overlap between the susceptibility genes of IBD and AS \[[@pone.0237219.ref001], [@pone.0237219.ref007], [@pone.0237219.ref012], [@pone.0237219.ref013]\], and a strong correlation between *FUT2*/*FUT3* and IBD \[[@pone.0237219.ref016], [@pone.0237219.ref020], [@pone.0237219.ref021]\], it was hypothesized that a link existed between the two genes and human susceptibility to AS. The results of this study suggested that *FUT3* polymorphisms were associated with the susceptibility to AS, and rs28362459-G might be a protective factor for AS. These findings suggested that some pathogenic factors might attach to Lewis antigens in the development of AS, and the lack of these antigens might block the process. This was consistent with the report that the adhesion of *Helicobacter pylori* to gastric mucosa correlated closely with Le^b^ in the host body, and the binding of *Escherichia coli* to the epithelial cells of intestinal mucosa needed a glycosylation structure \[[@pone.0237219.ref016], [@pone.0237219.ref018]\]. This might also be similar to the situation in which infection rates of norovirus, rotavirus, and *Helicobacter pylori* were commonly much lower in non-secretors than in secretors \[[@pone.0237219.ref020], [@pone.0237219.ref027], [@pone.0237219.ref028]\].

The results of the haplotype analyses revealed significant differences between the cases and the controls in the frequencies of haplotypes TT (rs812936--rs28362459) and TG (rs812936--rs28362459). Both the SNPs located in *FUT3* gene, indicating associations between the gene and AS at the haplotype level. These were consistent with the results at the allele level. Although no reports on the roles of these haplotypes can be found so far, the following points may provide a rational explanation for the results: It is clear the haplotype TG (rs812936--rs28362459) is one of the determinants of Lewis-negative status; and it is supposed that the haplotype TT (rs812936--rs28362459) may influence the structure and quantity of Lewis antigens.

This study discovered a potential susceptibility gene for AS, providing fresh data for exploring the etiology of AS. Meanwhile, this was the first report of a link between a blood group gene and AS, leading to new developments in the functional study of human blood groups. Although Shinebaum reported associations between ABO antigens of non-secretors and host susceptibility to spondyloarthropathies \[[@pone.0237219.ref029]\], the results proved to be false later \[[@pone.0237219.ref030]\]. Another study also suggested that the secretor status did not correlate with AS \[[@pone.0237219.ref031]\].

No significant differences were found between the cases and the controls in the frequencies of secretor status, Lewis status, and Lewis serotype. However, interactions on an additive scale were found between the Lewis status and the secretor status. The interactions might reflect the fact that the two factors jointly determined the type of Lewis HBGAs, which were likely the real molecules participating in the pathogenesis of AS. Moreover, the interaction between the *FUT3* polymorphisms and age was possibly related to the influence of age on the expression of Lewis antigens, and the influence might also be associated with the maturity of human gut microbiota \[[@pone.0237219.ref018], [@pone.0237219.ref019]\].

The possible reasons for not finding correlations between *FUT3* and AS at the phenotypic level were as follows. First, both *FUT2* and *FUT3* directly encode fucosyltransferase, which may have other biological functions besides determining the human secretor status and Lewis antigens. These functions may play varied roles in the development of AS. Second, the synthesis of the Lewis HBGAs complex, such as ALe^b^, is also influenced by *FUT1* and *ABO* genes, besides being controlled by *FUT3*. Finally, the Lewis serotypes in this study were inferred only from genotyping results, with no verifications using serological and salivary tests due to specimen limitations.

This study found multiple associations between rs28362459 and the clinical manifestations of AS at the genetic and phenotypic levels. Generally speaking, rs28362459-G, Lewis-negative status, and Le(a-b-) serotype might correlate with several aggravated disease indexes. These demonstrated to some extent that disease activity, functional impairments, and imaging changes in AS were also highly heritable \[[@pone.0237219.ref001]\]. As mentioned earlier, rs28362459-G might undermine the development of AS, but it was also associated with some severer clinical manifestations. These seemingly inconsistent results indicated that *FUT3* might play complicated roles in the pathogenesis of AS. A probable cause for the results was that rs28362459-G might bring about multiple changes in human gut microbiota, and further affect host immune functions. This could be similar to the situation in which the intestinal flora in a non-secretor's colon changed significantly in both structure and function among patients with CD \[[@pone.0237219.ref032], [@pone.0237219.ref033]\].

As with other case--control studies, this study also had some shortcomings. Correlations were found only between the genes and AS, but relevant mechanisms were not explored. This study involved only *FUT2* and *FUT3* genes, but did not include *FUT1* and *ABO* genes, which were also related to HBGAs. Therefore, the results of this study had certain one-sidedness. Moreover, due to the limited sample size, the power of analysis was affected to some extent for some subgroups. Due to the limited quality of questionnaire data, some analyses could not be carried out, such as the correlations between *FUT3* and relevant laboratory variables. Due to the limited size of untreated cases, the combination of treated and untreated cases, without statistical difference in nonparametric tests, was used in the analyses of associations between the gene polymorphisms and disease indexes. This might bring some bias.

To verify the findings of this study and further uncover the underlying mechanisms, researchers can investigate the compositional and functional characteristics of intestinal flora among patients with AS in the future. Furthermore, they can establish proper animal models of AS and explore the roles of HBGAs by blocking the expression of *FUT2* or *FUT3*. The findings may help in deepening the understanding of the associations between the *FUT3* gene and AS, and also in developing new treatment strategy for AS.

Conclusions {#sec014}
===========

*FUT3* gene polymorphisms correlated with human susceptibility to AS, both at the allele and haplotype level. Rs28362459-G might decrease the susceptibility, but enhance part of disease indexes of AS. This study highlighted the probability of wide associations between the blood group antigens and human autoimmune diseases.

Supporting information {#sec015}
======================

###### STROBE statement---checklist of items that should be included in reports of observational studies.

(DOCX)

###### 

Click here for additional data file.

###### Genotyping results of all the analyzed SNPs.

(PDF)

###### 

Click here for additional data file.

###### Genotype frequencies (left) and allele frequencies (right) of rs28362459 between patients with AS and healthy controls.

(PDF)

###### 

Click here for additional data file.

###### Demographic and clinical characteristics of total participants.

(PDF)

###### 

Click here for additional data file.

###### Questionnaire for AS in Chinese.

(PDF)

###### 

Click here for additional data file.

###### Questionnaire for AS in English.

(PDF)

###### 

Click here for additional data file.

###### 

(XLSX)

###### 

Click here for additional data file.

The authors are grateful to all the participants for their involvement and contributions to this study. They also thank the physicians at the Department of Rheumatology and Immunology, the First Affiliated Hospital of Anhui Medical University, for their help.

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.
